Prosolia enter technology license agreement Prosolia.

Related StoriesThermo Scientific Scientific launches HyPerforma SUM DS 300 program for multiple usesThermo Fisher Scientific launches Brilliance GBS AgarNew pre-validated fluorinated fragment library boosts drug screening efficiency Our contract with AB SCIEX further strengthens our position as the first choice in ambient ionization mass spectrometry systems, said Justin Wiseman, CEO and President of Prosolia. We envision several new products arising out of Dr. Van Berkel’s inventions and so are excited to utilize him and his group on these projects.And unlike additional psychiatric drugs such as for example risperidone or olanzapine, lithium was not associated with significant pounds gain, the researchers found. As well, non-e of the sufferers taking lithium had significant drug-related side effects, the team said. The study, published Oct. 12 in the journal Pediatrics, was funded by the U.S. National Institute of Child Health and Human Development. The results can assist doctors when deciding what medication to prescribe for short-term treatment of children and teens with bipolar disorder, said Findling, who is also director of child and adolescent psychiatry at the Johns Hopkins Children’s Center. The analysis was short in duration relatively, nevertheless, and Findling said that the effects of long-term use of lithium in youngsters are being assessed, like the risk of weight gain, and kidney and thyroid problems.